Not Yet RecruitingPhase 2

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

China40 participantsStarted 2024-06-01

Plain-language summary

To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up;
✓. Aged 18-75 years old (including 18 and 75 years old)
✓. male or female
✓. Histologically or cytologically confirmed adenocarcinoma of the pancreas
✓. Unresectable pancreatic cancer according to radiographic criteria (CT or MRI scans) or exploration( NCCN guidelines were referred): (1)The portal and superior mesenteric vein could not be reconstructed safely due to tumor invasion, venous occlusion, or involvement of a large area of the superior mesenteric vein jejunal branch (2)If pancreatic head/uncinate tumor: tumor contacts superior mesenteric artery or celiac trunk artery \>180 degrees. If pancreatic body tail tumor: tumor contacts the superior mesenteric artery or celiac trunk artery\>180 degrees, and tumor contacts the celiac trunk artery and infiltrates the abdominal aorta.
✓. Without distant metastasis as defined by CT or MRI scan of the chest, abdomen and pelvis
✓. No prior systematic treatment for advanced pancreatic cancer
✓. At least one measurable lesion was required. (Response evaluation criteria in Solid Tumors, RECIST, version 1.1)

✕. Participants had a second primary malignancy detected prior to the first dose of study treatment, or has other malignancies diagnosed within 5 years prior to the first dose of study treatment, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ;

Surgical conversion rate

Timeframe: Time from the first treatment up to 24 weeks

NCT IDNCT06361030

SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

Heshui Wu

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up;
✓. Aged 18-75 years old (including 18 and 75 years old)
✓. male or female
✓. Histologically or cytologically confirmed adenocarcinoma of the pancreas
✓. Unresectable pancreatic cancer according to radiographic criteria (CT or MRI scans) or exploration( NCCN guidelines were referred): (1)The portal and superior mesenteric vein could not be reconstructed safely due to tumor invasion, venous occlusion, or involvement of a large area of the superior mesenteric vein jejunal branch (2)If pancreatic head/uncinate tumor: tumor contacts superior mesenteric artery or celiac trunk artery \>180 degrees. If pancreatic body tail tumor: tumor contacts the superior mesenteric artery or celiac trunk artery\>180 degrees, and tumor contacts the celiac trunk artery and infiltrates the abdominal aorta.
✓. Without distant metastasis as defined by CT or MRI scan of the chest, abdomen and pelvis
✓. No prior systematic treatment for advanced pancreatic cancer
✓. At least one measurable lesion was required. (Response evaluation criteria in Solid Tumors, RECIST, version 1.1)

✕. Participants had a second primary malignancy detected prior to the first dose of study treatment, or has other malignancies diagnosed within 5 years prior to the first dose of study treatment, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ;